The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The pseudogene DUXAP10 contributes to gefitinib resistance in NSCLC by repressing OAS2 expression

Published:2022-11-01 Issue: Volume: Page:
ISSN:1672-9145
Container-title:Acta Biochimica et Biophysica Sinica
language:en
Short-container-title:ABBS

Author:

Ren Shengnan,Zhu Ya,Wang Siying,Zhang Qinqiu,Zhang Niu,Zou Xiaoteng,Wei Chenchen,Wang Zhaoxia

Publisher

China Science Publishing & Media Ltd.

Subject

General Medicine,Biochemistry,Biophysics

Link

https://engine.scichina.com/doi/pdf/A956BDD47EDA4B81B907329D2BA57B37

Reference29 articles.

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin, 2021, 71: 7-33.

2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med, 2002, 346: 92-98.

3. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol, 2007, 18: 317-323.

4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362: 2380-2388.

5. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med, 2008, 359: 1367-1380.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14

2. circIARS: a potential plasma biomarker for diagnosing non-small cell lung cancer;Acta Biochimica et Biophysica Sinica;2024-04-01

3. Exploring the interplay between methylation patterns and non-coding RNAs in non-small cell lung cancer: Implications for pathogenesis and therapeutic targets;Heliyon;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3